+ Filter
Loading...
Custom Services order now ship next day

CD39

Loading...

Anti-CD39 Products

More Infomation

Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag

More Infomation

Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us

For Research Use Only. Not For Clinical Use.


At Creative Biolabs, we're passionately committed to offering high-end recombinant antibodies. Crafted with meticulous attention to stringent standards and bolstered by exceptional technical support, our products are designed to propel CD39 research forward. Our unwavering pursuit of excellence guarantees researchers reliable resources for comprehensive biological and clinical studies, aiming to drive breakthroughs in exploring CD39's disease-related roles and therapeutic prospects.

CD39: A Significant Target in Cancer and autoimmune diseases

CD39, a cell surface enzyme, plays a pivotal part in regulating immune responses and metabolism, mainly by degrading extracellular nucleotides, which in turn impacts the immune microenvironment. This enzyme has drawn significant attention due to its involvement in various diseases. For example, in cancer, the overexpression of CD39 on tumor and immune cells within the tumor microenvironment can inhibit anti-tumor immunity and exploring CD39's role here may lead to the development of new therapies that reverse immune suppression and improve the effectiveness of cancer immunotherapies. Additionally, in autoimmune diseases like rheumatoid arthritis and multiple sclerosis, the dysregulation of CD39 can cause inflammation, and researching CD39 in these diseases might identify novel therapeutic targets for modulating immune responses and reducing disease symptoms. In short, studying CD39 holds great potential for enhancing the diagnosis and treatment of diseases characterized by immune dysregulation.

Alternative Names

ENTPD1; SPG64; ATP-DPH; ATPDase; NTPDase-1

Background

The antibodies against human CD39 can be used for the treatment or prevention of cancers and infectious diseases.

Anti-CD39 rAb Products

We are wholeheartedly dedicated to presenting top-notch antibody products. Our experienced scientists use advanced tech and strict quality control. They strive to meet the diverse research needs of those studying CD39's role in immunity, metabolism, and diseases. Whether for basic or clinical research, our products are reliable tools every step of the way.

Cat. No. Product Name Target Species Host Species Applications
TAB-123CL Anti-Human CD39 Recombinant Antibody Human Human ELISA
TAB-159LC Mouse Anti-CD39 Recombinant Antibody Human Mouse FC; Inhib; FuncS
HPAB-0177-CN Mouse Anti-ENTPD1 Recombinant Antibody Human Mouse ELISA; FC
HPAB-M0475-YC Mouse Anti-ENTPD1 Recombinant Antibody (clone mAb1) Human Mouse Inhib
HPAB-M0477-YC Mouse Anti-ENTPD1 Recombinant Antibody (clone mAb3) Human Mouse ELISA

Customer Reviews

Excellent
E**ie
Anti-Human CD39 Recombinant Antibody (Cat#: TAB-123CL)
During my research on cancer immunotherapy, I made use of the anti-human CD39 recombinant antibody and implemented ELISA for detection purposes. The outcomes were quite remarkable. The antibody efficiently recognized CD39 expression within both tumor tissues and immune cells. This furnished crucial understandings of the immune microenvironment, greatly propelling my study forward and establishing a solid foundation for formulating novel cancer treatment strategies centered around CD39.
17/Mar/2022
Excellent
H**di
Mouse Anti-CD39 Recombinant Antibody (Cat#: TAB-159LC)
While conducting research on CD39's function in inflammation, I utilized the mouse anti-CD39 recombinant antibody and carried out flow cytometry for detection. The results were highly impressive. The antibody successfully detected CD39 expression on the surfaces of immune cells. This reagent was essential for the progress of my research, offering more profound insights into the significance of CD39 during inflammatory processes.
7/Jun/2023

rAb Production

Boasting years of in-depth experience in vector design, cell transfection, and large-scale antibody production, we provide an all-inclusive service. Starting from gene synthesis, we guide customers through every step until the final antibody production. Our meticulous quality control is implemented at each stage, guaranteeing that clients obtain antibodies with the highest quality and remarkable stability.

Featured Anti-CD39 Recombinant Antibody Production PlatformsFig.1 Milligram-scale anti-CD39 recombinant antibody production. (Creative Biolabs Original)
Fig.1 Milligram-scale recombinant antibody production.

Fig.2 Gram-scale anti-CD39 recombinant antibody production. (Creative Biolabs Original)Fig.2 Gram-scale recombinant antibody production.

rAb Modalities

Creative Biolabs extends a warm welcome to researchers by presenting an extensive array of high-caliber recombinant antibodies. These come in multiple formats. For instance, full length antibodies offer complete functionality, while scFv provides high flexibility. Our standardized production procedures, paired with premier services, ensure that researchers' multifaceted needs are met. From initial consultation to final product delivery, we're with you, providing state-of-the-art antibody solutions.

Fig.3 Full Length Anti-CD39 Recombinant Antibody Production and Modalities. (Creative Biolabs Original)Fig.3 Full Length Anti-CD39 Recombinant Antibody Production and Modalities.

Drug Information Targeting CD39

Table 1. Therapeutic approaches targeting CD39 in clinical development.

Research phase Company Classification Indications Details
Phase II Novartis Biologics Acute kidney injury This is a recombinant human CD39 enzyme developed at Novartis. The company is conducting phase II clinical trials for the intravenous treatment of patients with sepsis-associated acute kidney injury and patients at risk for acute kidney injury following cardiac surgery.
Phase II AbbVie Biologics Cancer It is a monoclonal antibody that targets ectonucleoside triphosphate diphosphohydrolase 1 (ENTPD1, CD39) in phase II clinical development at Trishula Therapeutics, a spin-off of Tizona Therapeutics, as first-line treatment of metastatic pancreatic ductal adenocarcinoma, in combination with chemotherapy, with or without budigalimab.
Phase II Surface Oncology Biologics Cancer It is a surface Oncology's human monoclonal antibody targeting CD39, was evaluated in phase II clinical trials for metastatic castration-resistant prostate cancer.
Phase II AstraZeneca
Innate Pharma
Biologics Cancer It is a humanized monoclonal antibody targeting CD39, is in phase II clinical development at Innate Pharma for the treatment of non-small cell lung cancer (NSCLC), and in early clinical development for the treatment for patients with advanced solid tumors, both as monotherapy and in combination with oleclumab and/or durvalumab.
Phase I Arcus Biosciences Biologics Cancer It is in early clinical development at Arcus Biosciences as an intravenous anticancer immunotherapeutic.
Phase I Beijing Eirene Biotech Biologics Cancer It is a fully human anti- CD39 monoclonal antibody jointly developed by Junshi Biosciences and Beijing Eirene Biotech in early clinical evaluation as monotherapy in patients with advanced malignant solid tumors or lymphomas.
Phase I Elpiscience BioPharma Biologics Cancer This is a first-in-class anti-CD39xTGF-beta bispecific antibody in phase I development at Elpiscience BioPharma for the treatment of patients with advanced solid tumors.
Phase I Elpiscience BioPharma Biologics Cancer This is a humanized monoclonal antibody targeting CD39 in early clinical development at Elpiscience Biopharmaceuticals for the treatment of locally advanced or metastatic solid tumors.

Should you need more details about the target CD39, don't hesitate to reach out at your leisure. Our team, composed of experts well-versed in CD39-related research, is fully prepared to handle all your inquiries. Whether it's clarifying research concepts or offering product-related advice, we're eager to answer your questions and back your research efforts.

Go to compare

Go to compare